The present invention provides a compound represented by general formula (I) (in the formula: A is a benzene ring, pyridine ring, or the like； Y1 is an alkylene group having 1-6 carbon atoms, or the like； Y2 is a single bond or the like； Z is -C(=O)-NHSO2R6, an acidic 5-membered heterocycle group, or the like； R1 is a hydrogen atom or the like； R2 is a phenyl group, a 5-membered aromatic heterocycle group, or the like； R3 is a halogen atom, an alkoxy group having 1-6 carbon atoms, or the like； R4 is a hydrogen atom, a halogen atom, or the like； R5 is a hydrogen atom or the like； and R6 represents an alkyl group having 1-6 carbon atoms, or the like) having EP1 receptor antagonism, and a pharmacologically acceptable salt of same. Furthermore, the compound (I) can be used as a therapeutic drug or a preventative drug for various symptoms of LUTS, particularly OABs.本發明提供一種具有EP1受體拮抗作用之由本發明之通式(I)[式中，A為苯環、吡啶環等，Y1為C1-6伸烷基等，Y2為單鍵等，Z為-C(=O)-NHSO2R6、酸性5員雜環基等，R1為氫原子等，R2為苯基、5員環芳香族雜環基等，R3為鹵素原子、C1-6烷氧基等，R4為氫原子、鹵素原子等，R5為氫原子等，R6表示C1-6烷基等]所表示之化合物或其藥理學上容許之鹽。進而，本發明之化合物(I)可用作LUTS、尤其是OABs之各種症狀之治療藥或預防藥。
